November 9, 2010 (San Diego, California)— Top-line data from a trial of the investigational obesity drug lorcaserin (Arena Pharmaceuticals) in patients with diabetes have been reported and show that ...
Washington, DC - Eli Lilly and the FDA have revised the warning label on pergolide mesylate (Permax®) to include reports of cardiac valvulopathy that have occurred in a small number of patients.
To address concerns about the long-term safety of using dopamine agonists to treat patients with hyperprolactinemia Valassi and colleagues carried out a systematic review of the literature. Although ...
Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight. In this double-blind clinical trial, we randomly assigned 3182 obese or overweight adults (mean ...
A long-awaited study testing Arena Pharmaceuticals' weight loss drug lorcaserin in diabetic patients raises new safety concerns about the medicine, lowering the odds that the Food and Drug ...
SAN DIEGO, Sept. 11 -- Arena Pharmaceuticals announced today that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback